← Leaderboards
Joana M Murad
Celdara Medical, Llc
$11,241,450
Attributed
$13,011,678
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,011,678 · 10
By mechanism
R44$8,583,917 · 5
R42$2,949,803 · 1
R43$887,304 · 3
R41$590,654 · 1
Top collaborators
- Jason W. Botten5 shared
Most similar at Celdara Medical, Llc
Same institution · by research overlap
- Yolanda Camille Nesbeth$973,418
- Irena Ivanovska$523,007
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoCellsDoseSpecificityAntigensTissuesMouse ModelPreclinical DevelopmentLeadIn VitroDesignDiagnosisMonoclonal AntibodiesFda ApprovedChimeric Antigen ReceptorPreventT-LymphocyteAffectToxic EffectUnited StatesDisease ProgressionSiteAnimalsAntibodies
Grant awards (20)
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome$955,865
R42 · FY2025 · AI · contact PI
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)$921,394
R44 · FY2025 · NS · contact PI
Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes$999,828
R44 · FY2024 · DK · contact PI
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome$993,938
R42 · FY2024 · AI · contact PI
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)$921,486
R44 · FY2024 · NS · contact PI
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome$1,000,000
R42 · FY2023 · AI · contact PI
Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes$999,432
R44 · FY2023 · DK · contact PI
Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas$769,404
R44 · FY2023 · CA · contact PI
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)$466,950
R44 · FY2023 · NS · contact PI
Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas$712,718
R44 · FY2022 · CA · contact PI
CAR T platform to treat solid tumors$368,052
R43 · FY2022 · CA · contact PI
Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes$299,896
R44 · FY2022 · DK · contact PI
A Novel Broad-spectrum Antiviral Agent$290,738
R41 · FY2022 · AI · contact PI
A Novel Broad-spectrum Antiviral Agent$299,916
R41 · FY2021 · AI · contact PI
Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas$274,085
R44 · FY2021 · CA · contact PI
Cellular Immunotherapy for Systemic Sclerosis$730,718
R44 · FY2020 · AR · contact PI
A novel antibody therapy for Sin Nombre virus infection$294,252
R43 · FY2020 · AI · contact PI
Cellular Immunotherapy for Systemic Sclerosis$749,904
R44 · FY2019 · AR · contact PI
Complex 3-Dimensional in vitro Human Skin Tissue Models for Scleroderma$738,102
R44 · FY2019 · AR · contact PI
Cellular Immunotherapy for SSc$225,000
R43 · FY2017 · AR · contact PI